The use of rituximab in the treatment of disimmune polyneuropathy: a description of clinical cases and a literature review
Dysimmune neuropathies are heterogeneous group of acquired immune-mediated diseases, accompanied by damage to the peripheral nervous system. As a standard therapy, prednisolone and intravenous immunoglobulins are used. Also encouraging efficacy is demonstrated by the use of a genetically engineered...
Saved in:
Main Authors: | V. N. Kiselev, V. G. Potapenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2019-07-01
|
Series: | Нервно-мышечные болезни |
Subjects: | |
Online Access: | https://nmb.abvpress.ru/jour/article/view/327 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Clinical and Radiologic Features of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOGAD) in the City of Sakarya, Türkiye
by: Saadet Sayan, et al.
Published: (2025-07-01) -
Validation of the Neuropathy Impairment Score (NIS) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy
by: N. A. Suponeva, et al.
Published: (2024-12-01) -
Inflammatory Neuropathy Cause and Treatment (INCAT) Scale for the assessment of disability level in patients with chronic inflammatory demyelinating polyneuropathy: linguocultural ratification in Russia
by: А. S. Arestova, et al.
Published: (2021-12-01) -
Atypical variants of chronic inflammatory demyelinating polyneuropathy with benign course: a clinical observation for 8 patients without pathogenic therapy
by: D. A. Grishina, et al.
Published: (2020-08-01) -
Acute urinary retention as first sign of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) - Case report and literature review
by: Mariana Dias Capinha, et al.
Published: (2025-07-01)